Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia

Tokutaro Sato, Masao Oouchi, Hiroari Nagakubo, Tooru Chiba, Susumu Ogawa, Chiharu Sato, Kazuhiko Sugimura, Motosi Fukuda

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) is a common intermediate metabolite of cholesterol synthesis and ketone formation in the liver. In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia. Body mass index, diabetic control, and plasma free fatty acid levels were not changed during the study, and the plasma levels of cholesterol decreased significantly from 250±25 to 211±34 mg/100 ml after 6 months of pravastatin treatment. The plasma levels of acetoacetic acid also significantly decreased from 37.7±22.6 to 28.4±13.4 μmol/l, and those of 3-hydroxybutyric acid and total ketone bodies also tended to decrease after pravastatin treatment. These results suggest that pravastatin decrease ketone formation in hepatic mitochondria besides cholesterol synthesis in hepatic microsone.

Original languageEnglish
Pages (from-to)25-29
Number of pages5
JournalTohoku Journal of Experimental Medicine
Issue number1
Publication statusPublished - 1998 May


  • Cholesterol
  • Diabetes mellitus
  • Ketone bodies
  • Pravastatin


Dive into the research topics of 'Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia'. Together they form a unique fingerprint.

Cite this